Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Keytruda pembrolizumab Triple-negative breast cancer Reimburse with clinical criteria and/or conditions Complete
Dupixent dupilumab Asthma Reimburse with clinical criteria and/or conditions Complete
N/A rivaroxaban Venous thromboembolic events (VTE) Reimburse with clinical criteria and/or conditions Active
Beovu brolucizumab Diabetic macular edema Reimburse with clinical criteria and/or conditions Complete
Benlysta belimumab Lupus nephritis Reimburse with clinical criteria and/or conditions Complete
Imfinzi durvalumab Biliary tract cancer Reimburse with clinical criteria and/or conditions Complete
Dupixent dupilumab atopic dermatitis Reimburse with clinical criteria and/or conditions Complete
Pluvicto lutetium vipivotide tetraxetan Metastatic castration-resistant prostate cancer Reimburse with clinical criteria and/or conditions Complete
TBC abaloparatide Osteoporosis, postmenopausal women Withdrawn
Lynparza olaparib gBRCAm, HER2-negative high-risk early breast cancer Reimburse with clinical criteria and/or conditions Complete